A New Look at the 5?-Reductase Inhibitor Finasteride
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Finasteride is the first 5alpha-reductase inhibitor that received clinical approval for the treatment of human benign prostatic hyperplasia (BPH) and androgenetic alopecia (male pattern hair loss). These clinical applications are based on the ability of finasteride to inhibit the Type II isoform of the 5alpha-reductase enzyme, which is the predominant form in human prostate and hair follicles, and the concomitant reduction of testosterone to dihydrotestosterone (DHT). In addition to catalyzing the rate-limiting step in the reduction of testosterone, both isoforms of the 5alpha-reductase enzyme are responsible for the reduction of progesterone and deoxycorticosterone to dihydroprogesterone (DHP) and dihydrodeoxycorticosterone (DHDOC), respectively. Recent preclinical data indicate that the subsequent 3alpha-reduction of DHT, DHP and DHDOC produces steroid metabolites with rapid non-genomic effects on brain function and behavior, primarily via an enhancement of gamma-aminobutyric acid (GABA)ergic inhibitory neurotransmission. Consistent with their ability to enhance the action of GABA at GABA(A) receptors, these steroid derivatives (termed neuroactive steroids) possess anticonvulsant, antidepressant and anxiolytic effects in addition to altering aspects of sexual- and alcohol-related behaviors. Thus, finasteride, which inhibits both isoforms of 5alpha-reductase in rodents, has been used as a tool to manipulate neuroactive steroid levels and determine the impact on behavior. Results of some preclinical studies and clinical observations with finasteride are described in this review article. The data suggest that endogenous neuroactive steroid levels may be inversely related to symptoms of premenstrual and postpartum dysphoric disorder, catamenial epilepsy, depression, and alcohol withdrawal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurosteroids: endogenous regulators of the GABAA receptor
Belelli, D., & Lambert, J. J. (2005) · Nature reviews. Neuroscience · doi:10.1038/nrn1703 · Cited by 1,159
Purdy, R. H., Morrow, A. L., Moore, P. H., & Paul, S. M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.10.4553 · Cited by 951
Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression.
Thigpen, A. E., Silver, R. I., Guileyardo, J. M., Casey, M. L., McConnell, J. D., & Russell, D. W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116665 · Cited by 727
Deletion of steroid 5α-reductase 2 gene in male pseudohermaphroditism
Andersson, S., Berman, D. M., Jenkins, E. P., & Russell, D. W. (1991) · Nature · doi:10.1038/354159a0 · Cited by 643
GABAA receptor α4 subunit suppression prevents withdrawal properties of an endogenous steroid
Smith, S. S., Gong, Q. H., Hsu, F.-C., Markowitz, R. S., ffrench-Mullen, J. M. H., & Li, X. (1998) · Nature · doi:10.1038/31948 · Cited by 564
Bitran, D., Shiekh, M., & McLeod, M. (1995) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.1995.tb00744.x · Cited by 388
Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes
Griffin, L. D., & Mellon, S. H. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13512 · Cited by 387
Hunt, P. J., Gurnell, E. M., Huppert, F. A., Richards, C., Prevost, A. T., Wass, J. A. H., Herbert, J., & Chatterjee, V. K. K. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.12.7022 · Cited by 386
Anesthetic Effect of Steroid Hormones.
Selye, H. (1941) · Experimental Biology and Medicine · doi:10.3181/00379727-46-11907 · Cited by 375
van Niekerk, J. K., Huppert, F. A., & Herbert, J. (2001) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(01)00014-2 · Cited by 171
Cited by
Finasteride 5 mg and Sexual Side Effects: How Many of these are Related to a Nocebo Phenomenon?
Mondaini, N., Gontero, P., Giubilei, G., Lombardi, G., Cai, T., Gavazzi, A., & Bartoletti, R. (2007) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2007.00563.x · Cited by 299
Traish, A. M., Hassani, J., Guay, A. T., Zitzmann, M., & Hansen, M. L. (2011) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.02157.x · Cited by 275
Neurosteroid modulation of synaptic and extrasynaptic GABAA receptors
Herd, M. B., Belelli, D., & Lambert, J. J. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.03.007 · Cited by 206
Neurosteroids: Endogenous allosteric modulators of GABAA receptors
Lambert, J. J., Cooper, M. A., Simmons, R. D. J., Weir, C. J., & Belelli, D. (2009) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2009.08.009 · Cited by 180
Plasticity and function of extrasynaptic GABAA receptors during pregnancy and after delivery
Mostallino, M. C., Sanna, E., Concas, A., Biggio, G., & Follesa, P. (2009) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2009.06.013 · Cited by 32
Metadata
- Authors
- Finn, D. A., Beadles-Bohling, A. S., Beckley, E. H., Ford, M. M., Gililland, K. R., Gorin-Meyer, R. E., & Wiren, K. M.
- Venue
- CNS Drug Reviews
- Publisher
- Wiley
- Published
- 2006-03
- Volume
- 12
- Issue
- 1
- Pages
- 53-76
- ISSN
- 1080-563X (ISSN-L)
- 1527-3458
- OpenAlex
- W1520748992
- Cited by
- 179
- References
- 12
- FWCI
- 2.89
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A New Look at the 5?-Reductase Inhibitor Finasteride. https://app.cochat.ai/papers/10.1111/j.1527-3458.2006.00053.x
- The paper
- Finn, D. A., Beadles-Bohling, A. S., Beckley, E. H., Ford, M. M., Gililland, K. R., Gorin-Meyer, R. E., & Wiren, K. M. (2006). A New Look at the 5?-Reductase Inhibitor Finasteride. CNS Drug Reviews. https://doi.org/10.1111/j.1527-3458.2006.00053.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.